Literature DB >> 15106859

Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats.

Elisabetta Cagetti1, Kate J Baicy, Richard W Olsen.   

Abstract

Topiramate, a novel anticonvulsant drug, has CNS depressant activity including enhancement of GABAergic inhibitory synaptic transmission. Drugs of this pharmacological spectrum might have utility in assuaging drug addiction. This study analyzes the ability of TPM to reduce withdrawal signs in the kindling model of ethanol dependence: chronic intermittent ethanol (CIE) rats. After CIE, persistent withdrawal signs are shown by an increased seizure susceptibility to the convulsant drug pentylenetetrazol and increased anxiety measured on the elevated plus-maze. Topiramate increased significantly the PTZ seizure threshold in CIE but not in control rats. On the elevated plus-maze, Topiramate was markedly more effective in CIE rats than in controls. Topiramate may have a therapeutic efficacy in treating alcohol withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106859     DOI: 10.1097/00001756-200401190-00040

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

Review 1.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

2.  Ethosuximide Reduces Mortality and Seizure Severity in Response to Pentylenetetrazole Treatment During Ethanol Withdrawal.

Authors:  Melissa A Riegle; Melissa L Masicampo; Hong Qu Shan; Victoria Xu; Dwayne W Godwin
Journal:  Alcohol Alcohol       Date:  2015-04-12       Impact factor: 2.826

Review 3.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Update on the neurobiology of alcohol withdrawal seizures.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2005 Nov-Dec       Impact factor: 7.500

5.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 6.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 7.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

8.  Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex.

Authors:  V Echeverry-Alzate; E Giné; K M Bühler; J Calleja-Conde; P Olmos; M A Gorriti; R Nadal; F Rodríguez de Fonseca; J A López-Moreno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

10.  Effect of repeated treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol high-preferring rats.

Authors:  Jadwiga Zalewska-Kaszubska; Bartosz Bajer; Dorota Gorska; Dariusz Andrzejczak; Wanda Dyr; Przemysław Bieńkowski
Journal:  Psychopharmacology (Berl)       Date:  2012-07-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.